Skip to main content
Equibles
INO logo

INO · Inovio Pharmaceuticals, Inc.

Track INO — free

Use INO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about INO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.09 +0.19 (+21.10%) At close · Aug 14
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Customer concentration — top customer 100% of revenue

One customer — 100% of revenue (the years ended December 31, 2025 and 2024)

“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
View the 10-K filed Mar 12, 2026
Market Cap
$112.70M
Shares
103.40M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.09 Open$0.93 Day$0.90–1.10 52W close$0.66–2.87 Avg vol 30d4.2M Short int16.0M · 15.5% float · 3.1d Short vol26% Last earningsJul 29, 2026 DataJan 2024–Aug 2026 Filing10-Q · Aug 12

Raw chart and full-history price indicators begin at the captured split on Jan 25, 2024; bars on opposite sides are not compared.

Up next

Next earnings call
Oct 21, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Buy Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg −27%
      below
      Price vs 50-day avg +6%
      above
      RSI (14) 63
      neutral
      MACD trend Positive
      52-week position 20%
      mid-range
      Volume (OBV) Bullish div.
      accumulating
      Momentum
      relative strength
      Very Weak
      1-month return −3%
      trailing
      6-month return −40%
      trailing
      YTD return −37%
      this year
      Relative strength −54%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      +8% holders QoQ · +26 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      15.52% of float · ▲ +10.1% MoM · 3.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      108 holders — mid 3-yr range
      Squeeze score 100
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +19%
      Y/Y
      EPS growth +54%
      Y/Y
      Free cash flow $-88.9M
      Balance sheet $44.3M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 91%
      annualized · 1-yr
      Max drawdown −77%
      past year
      ATR 8.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Dec 31, 2023
      Operational net cash burn · first quarter of 2024 $26M
      Total net cash burn (including repayment of convertible senior n · first quarter of 2024 $43M
      Prior guidance period ended · from the 8-K filed May 13, 2026
      Operational net cash burn · second quarter of 2026 $18M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −27% Bearish
      Price vs 50-day avg
      +6% Bullish
      RSI (14)
      63 Neutral
      MACD trend
      Positive Bullish
      52-week position
      20% Neutral
      Volume (OBV)
      Bullish div. Bullish
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      +8% holders QoQ · +26 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      15.52% of float · ▲ +10.1% MoM · 3.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      108 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 20% Range high $3
      vs 200-day avg -27% vs 50-day avg +6%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      INO
      Inovio Pharmaceuticals, Inc.
      this stock
      		$112.70M -37.4% +19.4% — 15.5%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      108
      % held
      36.0%
      Net QoQ
      +5.1M sh
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      28
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      16.0M
      Days to cover
      3.1d
      Change
      +1.5M sh
      View
      Short Volume
      Short vol %
      26%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      751
      Value
      $871
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      55.6%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Christopher L. Jacobs
      Amount
      $1.0K–$15.0K
      Traded
      Sep 8, 2020
      View
      Financials
      Financials
      Revenue (FY)
      $65.3K
      Net income (FY)
      $-84.9M
      EPS diluted
      $-1.81
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 12, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $3.2K
      Shares
      5.7K
      Filed
      Jun 5, 2023
      View
      Exempt Offerings
      Offering
      $4.0M
      Filed
      Jan 24, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 29, 2026
      View
      Investor Relations
      Latest news
      INOVIO Reports Second Quarter 202…
      Published
      Aug 12, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Jan 25, 2024; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      INO +62.7% -2.7% -39.8% +60.3% -37.4%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +62.3% -7.1% -53.6% +56.4% -51.2%
      Key facts CIK 1055726 CUSIP 45773H409 13F (30d) 103 filings 101 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)